Form 4: BioCardia Director Stertzer Increases Stake in Company

Director Simon H. Stertzer reports purchasing additional shares of BioCardia, Inc. common stock in recent transactions.

Summary

• Simon H. Stertzer, a director of BioCardia, Inc., has reported changes in his beneficial ownership of the company's common stock.
• On March 3, 2025, Stertzer purchased 22,753 shares at a weighted average price of $2.3 per share.
• On March 4, 2025, he purchased an additional 15,536 shares at a weighted average price of $2.3 per share.
• Following these transactions, Stertzer directly owns 56,138 shares.
• Stertzer also has indirect ownership through several entities, including the Stertzer Family Trust (59,204 shares), Windrock Enterprises L.L.C. (15,379 shares), the Stertzer Gamma Trust (777 shares), and Stertzer Holdings LLC (6,102 shares).

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to insider buying, which suggests confidence in the company's future performance. However, it's a single transaction and doesn't guarantee future success.

Positives

• The director's purchase of shares could be interpreted as a positive signal about the company's prospects.

Industry Context

Insider buying is often seen as a positive sign, suggesting that those with the most knowledge of the company's prospects are optimistic about its future.

Stakeholder Impact

• Shareholders may view the director's purchase as a positive signal.
• The increased stake could align the director's interests more closely with those of other shareholders.

Key Dates